{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:35:53Z","timestamp":1778254553919,"version":"3.51.4"},"reference-count":85,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Reprod Med"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Progestogens (norethisterone acetate, medroxyprogesterone acetate, dydrogesterone, micronized progesterone, levonorgestrel, drospirenone, and trimegestone) added to estrogen for endometrial protection are reviewed. They can be given orally or vaginally, norethisterone acetate can also be given transdermally, and levonorgestrel can be given through the intrauterine route. Sequential use of progestogens protects the endometrium if exposure lasts for at least 12 days\/month; longer intervals are not safe. Continuous use of progestogens, whether oral, transdermal, or intrauterine, provides the most effective protection. Progestogen addition is accompanied with significant elevations in breast cancer risk, the largest drawback of progestogen use, and dydrogesterone, micronized progesterone, and a levonorgestrel intrauterine device may be safest in this regard. Progestogens also double deep vein thrombosis risk and diminish the positive effect of estrogen on colorectal cancer and vascular health. Recent data imply a neutral effect of progestogens in combination with estrogen on Alzheimer's disease risk, but the risk of vascular dementia is decreased. In conclusion, progestogens are a double-edged sword, effectively protecting the endometrium but causing several side effects and reducing many estrogen-induced benefits. With modern endometrial diagnostic tools, the safety of low-dose unopposed estrogen regimens should be assessed in a prospective controlled trial in women with an intact uterus.<\/jats:p>","DOI":"10.1055\/s-0045-1809186","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T19:19:31Z","timestamp":1747423171000},"page":"145-153","source":"Crossref","is-referenced-by-count":1,"title":["Progestogens in Menopausal Hormone Therapy: A Double-Edged Sword"],"prefix":"10.1055","volume":"43","author":[{"given":"Olavi","family":"Ylikorkala","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna M.","family":"Joensuu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heli","family":"Siitonen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomi S.","family":"Mikkola","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"09","key":"ref1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/aje\/153.9.865","article-title":"Factors associated with age at natural menopause in a multiethnic sample of midlife women","volume":"153","author":"E B Gold","year":"2001","journal-title":"Am J Epidemiol"},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/aje\/kwj282","article-title":"From menarche to menopause: trends among US women born from 1912 to 1969","volume":"164","author":"H B Nichols","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"07","key":"ref3","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American Menopause Society","volume":"29","author":"S S Faubion","year":"2022","journal-title":"Menopause"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.maturitas.2022.04.008","article-title":"Menopause, wellbeing and health: a care pathway from the European Menopause and Andropause Society","volume":"163","author":"I Lambrinoudaki","year":"2022","journal-title":"Maturitas"},{"issue":"19","key":"ref5","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1016\/j.jmb.2016.06.020","article-title":"Progesterone receptor signaling mechanisms","volume":"428","author":"S L Grimm","year":"2016","journal-title":"J Mol Biol"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/JME-19-0212","article-title":"90 years of progesterone: new insights into progesterone receptor signaling in the endometrium required for embryo implantation","volume":"65","author":"F J DeMayo","year":"2020","journal-title":"J Mol Endocrinol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13697130500148875","article-title":"Pharmacology of estrogens and progestogens: influence of different routes of administration","volume":"8","author":"H Kuhl","year":"2005","journal-title":"Climacteric"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.contraception.2015.01.008","article-title":"A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women","volume":"91","author":"A Dinh","year":"2015","journal-title":"Contraception"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.3390\/jcm12103388","article-title":"Understanding progestins: from basics to clinical applicability","volume":"12","author":"M Garc\u00eda-S\u00e1enz","year":"2023","journal-title":"J Clin Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-3-319-70178-3_12","article-title":"Role of estrogens in the regulation of liver lipid metabolism","author":"B T Palmisano","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1016\/j.jaip.2023.07.050","article-title":"Progestogen hypersensitivity","volume":"11","author":"S E Chiarella","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"101815","DOI":"10.1016\/j.beem.2023.101815","article-title":"Progestogens for endometrial protection in combined menopausal hormone therapy: a systematic review","volume":"38","author":"P Stute","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/AOG.0b013e31817d452b","article-title":"The relationship of bleeding patterns to daily reproductive hormones in women approaching menopause","volume":"112","author":"B J Van Voorhis","year":"2008","journal-title":"Obstet Gynecol"},{"key":"ref14","first-page":"dgae677","article-title":"Frequent use of premenopausal progestin in prior pre-eclamptic women","author":"J M Joensuu","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12905-023-02408-x","article-title":"Pre-eclampsia during pregnancy and risk of endometrial cancer: a systematic review and meta-analysis","volume":"23","author":"H Jordao","year":"2023","journal-title":"BMC Womens Health"},{"issue":"09","key":"ref16","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/GME.0000000000001806","article-title":"Preeclampsia and cancer risk in women in later life: a systematic review and meta-analysis of cohort studies","volume":"28","author":"F Wang","year":"2021","journal-title":"Menopause"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jama.1996.03530290040035","article-title":"Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen\/Progestin Interventions (PEPI) Trial","volume":"275","author":"H L Judd","year":"1996","journal-title":"JAMA"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/aje\/kwu146","article-title":"Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008","volume":"180","author":"A Fournier","year":"2014","journal-title":"Am J Epidemiol"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/AOG.0b013e3181bea950","article-title":"Endometrial cancer in postmenopausal women using estradiol-progestin therapy","volume":"114","author":"S Jaakkola","year":"2009","journal-title":"Obstet Gynecol"},{"issue":"9470","key":"ref20","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(05)66455-0","article-title":"Endometrial cancer and hormone-replacement therapy in the Million Women Study","volume":"365","author":"V Beral","year":"2005","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jsbmb.2013.05.001","article-title":"Menopausal hormone therapy and risk of endometrial cancer","volume":"142","author":"L A Brinton","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/20533691211064037","article-title":"Developing the women's health strategy: the British Menopause Society's recommendations to the department of health and social care's call for evidence","volume":"28","author":"H Hamoda","year":"2022","journal-title":"Post Reprod Health"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/0002-9378(95)90095-0","article-title":"Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses","volume":"172","author":"T H Raudaskoski","year":"1995","journal-title":"Am J Obstet Gynecol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/0002-9378(95)90573-1","article-title":"Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy","volume":"172","author":"S P Suhonen","year":"1995","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"ref26","first-page":"CD007245","article-title":"Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen","volume":"2015","author":"S Dominick","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"09","key":"ref27","first-page":"CD012658","article-title":"Levonorgestrel-releasing intrauterine system for endometrial hyperplasia","volume":"9","author":"T Mittermeier","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"ref28","first-page":"13","article-title":"Abnormal bleeding during menopause hormone therapy: insights for clinical management","volume":"6","author":"S F de Medeiros","year":"2013","journal-title":"Clin Med Insights Womens Health"},{"issue":"02","key":"ref29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/bmjsrh-2020-200619","article-title":"Norethisterone and its acetate - what's so special about them?","volume":"47","author":"E Huvinen","year":"2021","journal-title":"BMJ Sex Reprod Health"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"R306","DOI":"10.1186\/bcr994","article-title":"Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle","volume":"7","author":"M AH Navarrete","year":"2005","journal-title":"Breast Cancer Res"},{"issue":"03","key":"ref31","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/gme.0b013e31812f7b55","article-title":"Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought","volume":"15","author":"L Speroff","year":"2008","journal-title":"Menopause"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"J E Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/aje\/kwaa210","article-title":"Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50\u201359 years of age","volume":"190","author":"R L Prentice","year":"2021","journal-title":"Am J Epidemiol"},{"issue":"01","key":"ref35","first-page":"CD004143","article-title":"Long-term hormone therapy for perimenopausal and postmenopausal women","volume":"1","author":"J Marjoribanks","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09513590.2016.1248932","article-title":"Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis","volume":"33","author":"Z Yang","year":"2017","journal-title":"Gynecol Endocrinol"},{"issue":"05","key":"ref37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/GME.0000000000002335","article-title":"Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses","volume":"31","author":"S H Baik","year":"2024","journal-title":"Menopause"},{"issue":"03","key":"ref38","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/ije\/26.3.476","article-title":"Hysterectomy and subsequent risk of cancer","volume":"26","author":"R Luoto","year":"1997","journal-title":"Int J Epidemiol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2019","journal-title":"Lancet"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"m3873","DOI":"10.1136\/bmj.m3873","article-title":"Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases","volume":"371","author":"Y Vinogradova","year":"2020","journal-title":"BMJ"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"115340","DOI":"10.1016\/j.ejca.2025.115340","article-title":"Update of the impact of menopausal hormone therapy on breast cancer risk","volume":"220","author":"H Siitonen","year":"2025","journal-title":"Eur J Cancer"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbrc.2022.11.077","article-title":"The transcriptional activity of progestins used in contraception and menopausal hormone therapy via progesterone receptor A is dependent on the density of the receptor","volume":"639","author":"M Cartwright","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"106440","DOI":"10.1016\/j.jsbmb.2023.106440","article-title":"Progestins and breast cancer hallmarks: the role of the ERK1\/2 and JNK pathways in estrogen receptor positive breast cancer cells","volume":"237","author":"R Louw-du Toit","year":"2024","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/AOG.0b013e31818e8cd6","article-title":"Breast cancer risk in postmenopausal women using estradiol-progestogen therapy","volume":"113","author":"H Lyytinen","year":"2009","journal-title":"Obstet Gynecol"},{"issue":"02","key":"ref45","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/ijc.24738","article-title":"A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well","volume":"126","author":"H K Lyytinen","year":"2010","journal-title":"Int J Cancer"},{"issue":"01","key":"ref46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-007-9523-x","article-title":"Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study","volume":"107","author":"A Fournier","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"04","key":"ref47","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s11154-024-09882-0","article-title":"Diagnostic and therapeutic use of oral micronized progesterone in endocrinology","volume":"25","author":"E Memi","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"issue":"02","key":"ref48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1471-0528.2002.01167.x","article-title":"Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response","volume":"109","author":"T Raudaskoski","year":"2002","journal-title":"BJOG"},{"issue":"06","key":"ref49","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00404-022-06640-y","article-title":"Influence of the levonorgestrel-releasing intrauterine system on the risk of breast cancer: a systematic review","volume":"307","author":"A Z\u00fcrcher","year":"2023","journal-title":"Arch Gynecol Obstet"},{"issue":"04","key":"ref50","doi-asserted-by":"crossref","first-page":"450.e1","DOI":"10.1016\/j.ajog.2024.05.011","article-title":"Association of levonorgestrel-releasing intrauterine device with gynecologic and breast cancers: a national cohort study in Sweden","volume":"231","author":"H Yi","year":"2024","journal-title":"Am J Obstet Gynecol"},{"issue":"05","key":"ref51","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10654-016-0116-z","article-title":"The influence of hormone therapies on colon and rectal cancer","volume":"31","author":"L S M\u00f8rch","year":"2016","journal-title":"Eur J Epidemiol"},{"issue":"08","key":"ref52","doi-asserted-by":"crossref","first-page":"e1003731","DOI":"10.1371\/journal.pmed.1003731","article-title":"Menopausal hormone therapy and women's health: an umbrella review","volume":"18","author":"G Q Zhang","year":"2021","journal-title":"PLoS Med"},{"issue":"03","key":"ref53","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/PPO.0000000000000591","article-title":"Menopausal hormone replacement therapy and reduction of all-cause mortality and cardiovascular disease: it is about time and timing","volume":"28","author":"H N Hodis","year":"2022","journal-title":"Cancer J"},{"issue":"11","key":"ref54","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1158\/1055-9965.EPI-09-0596","article-title":"Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II","volume":"18","author":"J S Hildebrand","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"9574","key":"ref55","first-page":"1703","article-title":"Million Women Study C","volume":"369","author":"V Beral","year":"2007","journal-title":"Bull Green J Reeves G Ovarian Cancer Horm Replace Ther Million Women Study Lancet."},{"issue":"07","key":"ref56","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/ijc.28167","article-title":"Effect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer \u2013 a population-based case control study from Finland","volume":"133","author":"V Koskela-Niska","year":"2013","journal-title":"Int J Cancer"},{"issue":"05","key":"ref57","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/AOG.0000000000001387","article-title":"Association between menopausal estrogen-only therapy and ovarian carcinoma risk","volume":"127","author":"A W Lee","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3109\/13697137.2012.663818","article-title":"Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy - a nationwide study","volume":"16","author":"V Koskela-Niska","year":"2013","journal-title":"Climacteric"},{"issue":"02","key":"ref59","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2012.04.045","article-title":"Primary fallopian tube carcinoma risk in users of postmenopausal hormone therapy in Finland","volume":"126","author":"V Koskela-Niska","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"05","key":"ref60","doi-asserted-by":"crossref","first-page":"e63347","DOI":"10.1371\/journal.pone.0063347","article-title":"Sex differences in age-related cardiovascular mortality","volume":"8","author":"T S Mikkola","year":"2013","journal-title":"PLoS One"},{"issue":"08","key":"ref61","first-page":"e153","article-title":"Heart disease and stroke statistics\u20142022 update: a report from the American Heart Association","volume":"145","author":"C W Tsao","year":"2022","journal-title":"Circulation"},{"issue":"03","key":"ref62","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0008-6363(01)00466-7","article-title":"Estrogen replacement therapy, atherosclerosis, and vascular function","volume":"53","author":"T S Mikkola","year":"2002","journal-title":"Cardiovasc Res"},{"issue":"03","key":"ref63","first-page":"CD002229","article-title":"Hormone therapy for preventing cardiovascular disease in post-menopausal women","volume":"2015","author":"H M Boardman","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"ref64","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1505241","article-title":"Vascular effects of early versus late postmenopausal treatment with estradiol","volume":"374","author":"H N Hodis","year":"2016","journal-title":"N Engl J Med"},{"key":"ref65","first-page":"60","article-title":"Estrogen and cardiovascular disease","volume":"84","author":"F Gersh","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/13697137.2023.2282690","article-title":"Menopausal hormone therapy and coronary heart disease: the roller-coaster history","volume":"27","author":"M Nudy","year":"2024","journal-title":"Climacteric"},{"issue":"07","key":"ref67","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group","volume":"280","author":"S Hulley","year":"1998","journal-title":"JAMA"},{"issue":"13","key":"ref68","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jama.297.13.1465","article-title":"Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause","volume":"297","author":"J E Rossouw","year":"2007","journal-title":"JAMA"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.maturitas.2023.04.271","article-title":"Reappraising 21 years of the WHI study: putting the findings in context for clinical practice","volume":"174","author":"P Stute","year":"2023","journal-title":"Maturitas"},{"issue":"01","key":"ref70","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12905-023-02788-0","article-title":"The benefits and risks of menopause hormone therapy for the cardiovascular system in postmenopausal women: a systematic review and meta-analysis","volume":"24","author":"Y Gu","year":"2024","journal-title":"BMC Womens Health"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"e078784","DOI":"10.1136\/bmj-2023-078784","article-title":"Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial","volume":"387","author":"T Johansson","year":"2024","journal-title":"BMJ"},{"issue":"07","key":"ref72","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1210\/jc.2015-4149","article-title":"Cardiac death risk in relation to the age at initiation or the progestin component of hormone therapies","volume":"101","author":"H Savolainen-Peltonen","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"04","key":"ref73","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1055\/s-0037-1615643","article-title":"Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women","volume":"85","author":"S Vehkavaara","year":"2001","journal-title":"Thromb Haemost"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"k4810","DOI":"10.1136\/bmj.k4810","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"364","author":"Y Vinogradova","year":"2019","journal-title":"BMJ"},{"issue":"02","key":"ref75","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0002-9149(03)00542-3","article-title":"Differing effects of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy postmenopausal women","volume":"92","author":"T E Strandberg","year":"2003","journal-title":"Am J Cardiol"},{"issue":"22","key":"ref76","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1161\/01.CIR.102.22.2687","article-title":"Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women","volume":"102","author":"S Vehkavaara","year":"2000","journal-title":"Circulation"},{"issue":"11","key":"ref77","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1210\/jc.2015-2237","article-title":"Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis","volume":"100","author":"K Mohammed","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"05","key":"ref78","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/GME.0000000000001945","article-title":"Different regimens of menopausal hormone therapy for improving sleep quality: a systematic review and meta-analysis","volume":"29","author":"Z Pan","year":"2022","journal-title":"Menopause"},{"issue":"03","key":"ref79","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1474-4422(20)30440-3","article-title":"New insights into atypical Alzheimer's disease in the era of biomarkers","volume":"20","author":"J Graff-Radford","year":"2021","journal-title":"Lancet Neurol"},{"issue":"03","key":"ref80","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbrc.2007.05.158","article-title":"Estrogen has anti-amyloidogenic effects on Alzheimer's \u03b2-amyloid fibrils in vitro","volume":"359","author":"A Morinaga","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"06","key":"ref81","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/GME.0b013e3182960cf8","article-title":"Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies","volume":"20","author":"P M Maki","year":"2013","journal-title":"Menopause"},{"issue":"11","key":"ref82","doi-asserted-by":"crossref","first-page":"e1004435","DOI":"10.1371\/journal.pmed.1004435","article-title":"Long-term cognitive effects of menopausal hormone therapy: findings from the KEEPS Continuation Study","volume":"21","author":"C E Gleason","year":"2024","journal-title":"PLoS Med"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"1350318","DOI":"10.3389\/fendo.2024.1350318","article-title":"Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition","volume":"15","author":"C Andy","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"l665","DOI":"10.1136\/bmj.l665","article-title":"Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study","volume":"364","author":"H Savolainen-Peltonen","year":"2019","journal-title":"BMJ"},{"issue":"03","key":"ref85","first-page":"870","article-title":"Lower death risk for vascular dementia than for Alzheimer's disease with postmenopausal hormone therapy users","volume":"102","author":"T S Mikkola","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"06","key":"ref86","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/1471-0528.12598","article-title":"Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial","volume":"121","author":"N Cherry","year":"2014","journal-title":"BJOG"}],"container-title":["Seminars in Reproductive Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0045-1809186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:32:24Z","timestamp":1761607944000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0045-1809186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":85,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2025,10,27]]},"published-print":{"date-parts":[[2025,6]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0045-1809186","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1526-8004","1526-4564"],"issn-type":[{"value":"1526-8004","type":"print"},{"value":"1526-4564","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]}}}